Key Takeaways
- Pharma margin story intact, Crop still bleeding: Pharma EBIT margin hit 10% on a 9-month basis (up from 5% YoY), while Crop Protection faces "a few more quarters of pain" from Chinese dumping despite 41% volume growth.
- Animal Health nears the starting line: Validation of seven products is complete under a global innovator contract; FY26 will be the first year of commercial revenue, with a 5-year target of INR400+ crores as a standalone division.
- CDMO pipeline is the growth engine: 13–14 pharma CDMO products in the pipeline, two nearing launch by end-FY26, and management targets CDMO overtaking generics toward a 60-40 revenue split.
- Project Pinnacle delivered strategy, not quantified savings: Management declined to quantify benefits realized vs remaining, describing the exercise as a strategic realignment rather than a cost-savings program with a completion percentage.
- What to watch next quarter: Whether Animal Health registrations convert to first commercial orders, the pace of Panoli facility ramp-up, and any stabilization signal in Crop Protection pricing.
Pharma: The Margin Recovery
- 9-month EBIT doubled: Pharma EBIT margin improved from 5% to 10% YoY on a 9-month basis, driven by product mix improvement and operating leverage. The Q3 standalone EBIT margin was up 450 bps YoY.
- QoQ drop is a phasing artifact: Customers asked to defer December shipments into January, compressing Q3 pharma EBIT sequentially. Management says the 9-month trend is the right lens.
- API volume recovery: The API business is seeing volume growth from successful global customer acquisitions and is expected to remain steady in coming quarters.
- CDMO share rising, not falling: When an analyst suggested CDMO percentage dropped from 80% to 56% in the quarter, management pushed back: "It has not dropped. It has gone up." On a 9-month basis, pharma CDMO is about 40% of the segment.
- Two NCEs in Phase III: Two NCE projects are making notable strides in Phase III clinical trials and expected to launch very soon, supporting growth as operations ramp in FY26 and FY27.
Hiremath: "A few years ago, this pipeline was a few products, then it became 5 to 6 products. Now we're talking of 13 to 14 products. As we go forward, the number of projects during -between Phase II B and Phase III will be at any given time, we're targeting to increase this number well beyond 14."
Crop Protection: Volume Up, Value Down
- Volume grew 41%, value degrew 3.3%: On a 9-month basis, Crop Protection shipped dramatically more volume but realized lower value, a direct consequence of intense pricing pressure and Chinese dumping in generics and commodities.
- "A few more quarters of pain": Management expects the sector to stabilize in the next 2 to 3 quarters, but near-term pressure persists. The company is retooling its product offerings toward NCEs and CDMO pipeline to shift away from commoditized products.
- Domestic demand rising: Rise in domestic demand is supporting own products and innovator RFPs, offering a partial offset to export pricing weakness.
- Pipeline beyond commodities: More than 8 active projects under filing or launch in the next 2 to 3 years, none of them commodity products. The mix includes proprietary off-patent and NCE on-patent chemistry, driving growth from FY27 onwards.
- New agrochem plant capitalized: The INR340-crore agrochem plant was capitalized last month, positioning the company for the CDMO and NCE pivot once demand materializes.
Animal Health: The Next Leg
- Validation is effectively global: Because the company is validating the product itself (not a customer-specific variant), the data package serves all customers simultaneously. Samples have been shipped globally for 12–14 months.
- Registration underway: Some products have already entered country-level registration. Lead time from validation to approval to sell in a given country is 14–16 months, depending on geography.
- FY26 is the commercialization year: Validation revenue winds down and commercial revenue begins toward the end of FY26. Management expects to sell some products "in the next quarter or so" as registrations come through.
- 5-year ambition: INR400+ crores: The company wants Animal Health to become an independent division with business in excess of INR400 crores over the next 5 years.
Swadi: "When we look at validation for the innovator customer, what we do is we basically are validating the product, right, for all customers. So, when the validation happens, it's not only for one customer, it's for all customers because we're scaling up the product and putting it into commercial and getting all the data for filing."
CDMO Pipeline & Growth Ambition
- Two products near launch: Two CDMO products are very close to launch, expected by end-FY26. Others follow in FY27 and beyond. Commercial supply from validation quantities of several NCE molecules begins end of calendar year 2026 into early 2027.
- CDMO to overtake generics: Management is working toward a 60-40 CDMO-to-generics revenue split, up from the current ~40% CDMO share in pharma.
- Per-molecule potential: Peak revenue per NCE CDMO molecule ranges from INR50 crores in the worst case to a few hundred crores in the best case.
- Crop CDMO pipeline: A strong pipeline of eight products from current and prospective clients; the company expects to strengthen its position among global innovators over the medium to long term.
- Food ingredients: Project progressing well, expected to achieve peak revenue in the next 2 to 3 years.
- Product launch cadence: A development pipeline of eight to nine products, with three to four launches anticipated annually.
Hiremath: "I think we are anticipating a growth in the next 3 to 5 years of high teens per year-on-year CAGR if you were to project ourselves out and we were sitting together here in FY '28, 3-4 years from now, and we have to review where the business was in FY '24 and where we are stepwise, we'll get there."
Margins, Capex & Capital Allocation
- Q3 EBITDA up 11% YoY: INR72 crores on revenue of INR448 crores. 9-month EBITDA grew 18% YoY to INR205 crores, with operating cash flow up INR102 crores on the same basis.
- Margin drivers: Operating leverage, cost improvement initiatives, and product mix improvement lifted the margin profile in Q3.
- 20% EBITDA target: Management aims to cross the 20% EBITDA margin barrier (last achieved 2–3 years ago) and then go beyond.
- FY26 capex: INR150–200 crores: 30–40% is replacement capex; the balance is debottlenecking and growth capex. The new Panoli multipurpose facility was capitalized last month, with ramp-up expected over the next 2 to 3 years.
- Interim dividend: Board recommended INR0.6 per share (30% of face value).
Hiremath: "Our aim is to cross the 20% barrier, which we were historically doing about 2, 3 years ago. So, our target is to cross that first and go beyond that also, yes."
Competitive Positioning & Unanswered Questions
- Why Hikal for CDMO? When asked what differentiates Hikal from 20+ high-quality Indian small-molecule CDMO peers, management described its position (top 5, R&D plus manufacturing expertise, differentiated technology) but did not articulate a specific competitive moat.
- Small-molecule resurgence: Asked why innovators are returning to small molecules, management declined to offer expertise on the trend, speculating only about drug delivery and affordability.
- Project Pinnacle quantification avoided: Management described Pinnacle as a strategic realignment covering manufacturing efficiency, organization gaps, product selection, growth drivers, and ESG goals, but provided no quantification of benefits realized vs remaining, despite a direct analyst request.
- U.S. tariffs: wait and watch: The China shift has been increasing over 12–18 months and Hikal sees opportunity, but management called the situation "volatile" and said "we'll have to wait and watch to see what the impact is."
Swadi: "But look, it's a volatile situation, right? We don't know how it's going to pan out, whether it's a negotiating tactic with the new administration."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Animal Health commercialization | First commercial revenues from some products as registrations come through | FY26 (toward end of FY26 for broader commercial revenue) |
| Animal Health scale target | Independent division with business in excess of INR400+ crores | 5 years |
| Pharma CDMO launches | Two products very close to launch; commercial supply of NCE validation quantities begins | End-FY26 for two products; end-CY26/early-FY27 for NCE commercial supply |
| CDMO revenue mix | CDMO to overtake generics, targeting 60-40 split | No date given |
| Overall EBITDA margin | Cross 20% barrier, then go beyond | No date given |
| Company revenue CAGR | Mid- to high teens year-on-year CAGR, on a base of INR2,000 crores | 3 to 5 years |
| Crop Protection pipeline | 8+ active projects under filing or launch, none commodity; drive growth | FY27 onwards |
| FY26 capex | INR150–200 crores (30–40% replacement, balance growth/debottlenecking) | FY26 |
| Panoli facility ramp-up | New multipurpose facility capitalized; ramp-up over next 2–3 years | 2–3 years |
| Crop Protection industry stabilization | Global crop protection industry expected to stabilize | Next 2–3 quarters |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Revenue | ₹448 cr, +3% YoY on a 9M basis |
| EBITDA | ₹72 cr, +11% YoY |
| EBITDA margin | 16.1%, +11% YoY EBITDA growth on flat revenue |
| Pharma revenue | ₹293 cr, +7.1% YoY on a 9M basis |
| Pharma EBIT margin | 11.3%, +450 bps YoY; 9M EBIT margin improved from 5% to 10% |
| Crop Protection revenue | ₹154 cr, -3.3% YoY on a 9M basis |
| Crop Protection EBIT margin | 9% |
| Operating cash flow | ₹102 cr positive, 9M YoY increase |
| Gross debt | ₹731 cr as of December 2024 |
| Capex | ₹140–150 cr guided for FY25; ₹150–200 cr planned annually thereafter |
| R&D spend | 4.5–5% of revenue |
| Pharma CDMO revenue share | ~40% on a 9M basis |
| Crop Protection CDMO revenue share | ~70% historically |
| Crop Protection volume growth | 41% on a 9M basis |
| Pharma volume growth | 3.7% on a 9M basis |